Endothelial Progenitor Cell Expansion via Density Gradient Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating vascular disorders, such as arterial dysfunction, are inadequate in promoting angiogenesis and neovascularization, particularly in cases where traditional therapies like drugs and revascularization procedures are ineffective.
Innovation Solution
The use of endothelial progenitor cells (EPCs), which are isolated, differentiated, and expanded from human peripheral blood, and then implanted to induce vasculogenesis and angiogenesis, involves a series of protocols including density gradient separation, culture medium enrichment, and surface coating with growth-enhancing molecules to enhance cell adhesion and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional revascularization procedures and drugs are used to treat arterial dysfunction, then some patients experience improvement, but a substantial proportion of patients continue to suffer from artery dysfunction-derived disease
Solution Approach 1:
The patent uses endothelial progenitor cells (EPCs) as intermediary agents that mediate between the treatment administration and the ischemic tissue. These cells migrate to the injured tissue and facilitate re-endothelialization, neovascularization, and vasculogenesis processes, providing a biological bridge that traditional mechanical revascularization procedures cannot achieve in severe cases.
Solution Approach 2:
The patent employs autologous EPCs that are harvested from the patient's own bone marrow or peripheral blood, expanded in vitro, and reinfused. These cells naturally migrate to the ischemic tissue and perform self-repair functions through differentiation into endothelial cells, secretion of growth factors, and fusion with injured tissue cells, eliminating the need for continuous external intervention.
2Productivity
If EPCs are isolated and expanded using conventional methods, then cell numbers increase, but the functional quality and differentiation capacity of the cells may be compromised
Solution Approach 1:
The patent applies different culture conditions to different stages of EPC expansion and differentiation. Initial expansion uses specific growth factors and medium compositions to maximize cell numbers, while subsequent differentiation stages use altered conditions (such as hypoxia, specific cytokines, or substrate coatings) to guide cells toward endothelial lineage. This staged approach with locally optimized conditions maintains both productivity and functional quality.
Solution Approach 2:
The patent employs dynamic culture conditions that change over time during the expansion and differentiation process. Culture media compositions, oxygen tensions, and growth factor concentrations are adjusted at different time points to first expand cell numbers and then direct differentiation. This temporal dynamics allows the system to optimize for cell proliferation initially and then for functional maturation, resolving the contradiction between quantity and quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the number of functional EPCs, leading to improved blood flow, capillary density, and tissue regeneration, effectively addressing the limitations of existing treatments for vascular disorders.
Implementation Method 1
applying blood to a first gradient suitable for selecting first-pass cells having a density less than 1.077 g/ml; applying the first-pass cells to a second gradient suitable for selecting second-pass cells having a density between 1.055 and 1.074 g/ml
Data Source
AI summary
A method is provided for use with extracted blood, including (a) applying blood to a first gradient suitable for selecting first-pass cells having a density less than 1.077 g/ml; (b) applying the first-pass cells to a second gradient suitable for selecting second-pass cells having a density between 1.055 and 1.074 g/ml; (c) increasing the number of cells having a density between 1.055 and 1.074 g/ml, by culturing the second-pass cells for a period lasting between 3 and 30 days; and (d) identifying endothelial progenitor cells in the cultured cells. Other embodiments are also described.